NICE, the body that makes reimbursement recommendations for England’s National Health Service, has given the thumbs down to Pfizer Inc.’s PARP inhibitor Talzenna (talazoparib) for the treatment of certain types of advanced breast cancer in preliminary guidance on 28 July, saying the drug is not a cost-effective use of NHS resources.
In it draft guidance, NICE cited Talzenna’s lack of overall survival benefit compared with chemotherapy as a main reason...